Mayur Narkhede, MD
Hematology & Oncology · Birmingham, ALNPI 1730529777
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $116,600 of the $192,850 with a category attached, or 60.5%. It is spread thinly across 22 manufacturers, the largest accounting for just 19.5%. Among hematology & oncology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $1009.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$38K
- Beone Medicines USA, Inc.$31K
- Lilly USA, LLC$26K
- Beigene USA, Inc.$23K
- AbbVie$21K
- ADC Therapeutics America, Inc.$16K
- plus $38K from 16 others
Across 538 payments — averaging $8972.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genmab A/s$3M
- Genentech, Inc.$860K
- TG Therapeutics, Inc.$315K
- Beone Medicines USA, Inc.$245K
- Gilead$102K
- Recordati_rare_diseases_inc.$88K
- plus $215K from 4 others
What the payments were for
- Consulting fees$57,68430%
- Speaking & faculty fees$116,60060%
- Travel & lodging$14,9088%
- Food & beverage$3,4702%
- Education$1890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 33 | $37,539 |
| Beone Medicines USA, Inc. | 20 | $30,593 |
| Lilly USA, LLC | 13 | $25,694 |
| Beigene USA, Inc. | 14 | $23,489 |
| AbbVie | 29 | $21,106 |
| ADC Therapeutics America, Inc. | 22 | $16,227 |
| AstraZeneca | 6 | $6,842 |
| Genentech, Inc. | 2 | $6,000 |
| Seagen Inc. | 4 | $5,881 |
| Recordati_rare_diseases_inc. | 5 | $5,145 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $4,725 |
| Ipsen Biopharmaceuticals, Inc | 3 | $2,727 |
| Gilead | 6 | $2,457 |
| Beigene, Ltd. | 3 | $2,014 |
| Janssen Scientific Affairs, LLC | 1 | $1,363 |
| Incyte Corporation | 12 | $391 |
| Secura Bio, Inc. | 3 | $257 |
| EUSA Pharma (US) LLC | 1 | $119 |
| Morphosys, US Inc. | 7 | $98 |
| Johnson & Johnson | 1 | $97 |
| Genmab U.S., Inc. | 1 | $58 |
| Epizyme, Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$192,850 in reported general payments places this provider in the 95th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 66 | $930,172 |
| VenclextaVenetoclax | 42 | $612,379 |
| BrukinsaZanubrutinib | 43 | $445,654 |
| JaypircaPirtobrutinib | 19 | $393,528 |
| ImbruvicaIbrutinib | 25 | $337,161 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $72,895 |
| Acyclovir | 72 | $1,122 |
| ValacyclovirValacyclovir Hcl | 12 | $674 |
| Ondansetron Hcl | 31 | $547 |
| Oxycodone Hcl | 38 | $349 |
| Allopurinol | 19 | $242 |
| Dexamethasone | 14 | $180 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $147 |
| Gabapentin | 14 | $135 |
| Prednisone | 53 | $132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $6,842 | $930,17266 claims |
| AbbVieVenclexta | $21,106 | $612,37942 claims |
| Beigene USA, Inc.Brukinsa | $23,489 | $445,65443 claims |
| Lilly USA, LLCJaypirca | $25,694 | $393,52819 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $4,725 | $337,16125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Birmingham
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
- Christos VaklavasBirmingham$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.